CD274 and non-small cell lung carcinoma: Of the 4,777 patients included in 9 clinical trials and 7 real-world studies that directly compared the clinical outcomes of anti-PD-1/PD-L1 immunotherapy (monotherapy or combined with chemotherapy) between smoker and non-smokers with NSCLC, 3,098 (64.85%) patients were current or former smokers.